Who can prescribe Strattera? NP vs MD in Texas

If you’ve been wondering whether you can access ADHD treatment without leaving your home, you’re not alone. Telehealth has revolutionized mental healthcare access, and for many people seeking non-stimulant ADHD medications like Strattera (atomoxetine), virtual care offers a convenient, effective pathway to treatment.

The short answer is yes—you can absolutely get non-stimulant ADHD medication prescribed through telehealth in most cases. Unlike controlled stimulant medications, non-stimulants face fewer regulatory barriers, making them particularly accessible through virtual platforms. But the full picture involves understanding federal rules, state-specific requirements, and what to expect from a legitimate telehealth evaluation.

Understanding Non-Stimulant ADHD Medications and Telehealth

What Makes Non-Stimulants Different?

Non-stimulant ADHD medications like Strattera (atomoxetine) occupy a unique position in the treatment landscape. Unlike Adderall, Ritalin, or Vyvanse—which are Schedule II controlled substances under federal law—Strattera is not classified as a controlled substance by the Drug Enforcement Administration (DEA). This distinction has enormous implications for telehealth prescribing.

Because Strattera doesn’t carry DEA scheduling, it’s exempt from the Ryan Haight Act’s requirement for an initial in-person medical evaluation before prescribing controlled substances online. This means qualified healthcare providers can evaluate you via video consultation, confirm an ADHD diagnosis using established clinical criteria, and electronically prescribe Strattera—all without you ever setting foot in a physical office.

How Non-Stimulants Work for ADHD

Strattera works differently than stimulant medications. It’s a selective norepinephrine reuptake inhibitor (SNRI) that gradually increases norepinephrine levels in the brain, helping improve attention, reduce impulsivity, and manage hyperactivity. Unlike stimulants that work within hours, Strattera typically requires 4–6 weeks to reach full effectiveness.

This medication is particularly valuable for people who:

• Have a history of substance use concerns that make stimulants inappropriate
• Experience uncomfortable side effects from stimulants
• Have certain coexisting conditions like anxiety or tic disorders
• Prefer a non-controlled medication for personal or professional reasons
• Need 24-hour symptom coverage (Strattera provides consistent effects, whereas some stimulants wear off)

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

The Current Federal Regulatory Landscape

DEA Telehealth Flexibilities Through 2025

The regulatory environment for telehealth prescribing remains in transition. During the COVID-19 pandemic, the DEA implemented temporary flexibilities allowing healthcare providers to prescribe controlled substances (Schedules II–V) via telehealth without a prior in-person examination. As of December 2025, the ‘Third Temporary Extension of COVID-19 Telemedicine Flexibilities’ remains in effect, extending these provisions through December 31, 2025.

While this primarily impacts stimulant medications, it’s important context for understanding the broader telehealth ADHD treatment landscape. The DEA is currently reviewing a potential fourth extension for 2026, though the final outcome remains uncertain.

For non-stimulant medications like Strattera, these temporary rules don’t even apply—there never was a federal prohibition on tele-prescribing non-controlled ADHD medications. Licensed providers have always been able to prescribe them via telehealth, as long as they meet standard-of-care requirements and hold proper state licensure.

What Happens After December 31, 2025?

If you’re considering telehealth for stimulant medications, be aware that current federal flexibilities expire at year-end unless extended. Without action, the Ryan Haight Act’s in-person requirement could resume for controlled substances in 2026. However, for patients seeking non-stimulant options, this regulatory uncertainty doesn’t affect access—Strattera and similar medications remain fully accessible via telehealth regardless of DEA policy changes.

The DEA has proposed a ‘Special Registration’ pathway that could create permanent telehealth prescribing options with additional safeguards, but this hasn’t been finalized as of late 2025.

State-by-State Telehealth Rules: What You Need to Know

While federal law sets the baseline, state regulations determine the practical reality of your telehealth access. The good news: no state outright bans telehealth treatment for ADHD. However, requirements vary considerably.

States with Minimal Restrictions

California, Illinois, and Pennsylvania have embraced telehealth with few special restrictions for ADHD care. In these states:

• No mandatory in-person examination for non-controlled medications
• Telehealth visits can establish a valid provider-patient relationship
• Standard-of-care principles apply, but the medium of care (video vs. in-person) doesn’t impose extra hurdles

California has been considering legislation (AB 1503) to further clarify that telehealth examinations satisfy prescription requirements, though this primarily addresses controlled substances.

New Hampshire recently modernized its approach. In August 2025, Senate Bill 252 took effect, removing the prior in-person requirement for controlled substance prescribing via telemedicine. Now, providers need only conduct an appropriate follow-up evaluation at least annually. For non-controlled medications, NH imposes virtually no special telehealth restrictions.

States with Moderate Requirements

Florida takes a nuanced approach. While generally telehealth-friendly, Florida law prohibits prescribing Schedule II stimulants via telehealth unless the medication treats a psychiatric disorder (ADHD qualifies), or the patient is hospitalized, in hospice, or in a nursing facility. For Strattera, Florida imposes no special restrictions.

Florida does require prescription drug monitoring program (PDMP) checks before every controlled substance prescription, and mandates video visits (not audio-only) for controlled medications. Still, for non-stimulant ADHD treatment, the pathway remains straightforward.

Texas supports telehealth for mental health conditions, with no blanket in-person requirement for ADHD treatment. The main Texas quirk involves prescriber type: nurse practitioners and physician assistants cannot prescribe Schedule II stimulants in regular outpatient settings (only in hospitals or hospice care). Physicians face no such limitation. For non-controlled Strattera, any qualified provider with proper credentials can prescribe via telehealth.

States with Stricter Oversight

Alabama maintains some of the nation’s strictest telehealth rules. The state requires an in-person visit within 12 months if you’re receiving ongoing telehealth treatment—with notable exceptions for mental health services. Additionally, Alabama historically required a licensed medical professional to be physically present with the patient during initial controlled substance telehealth visits (creating what some call the ‘Alabama Loophole’).

However, these restrictions don’t apply to non-controlled medications. If you’re seeking Strattera in Alabama, the 12-month rule is waived for psychiatric care, making access more feasible than headlines might suggest.

New York implemented new requirements in May 2025 that mandate an in-person evaluation before prescribing any controlled substance via telemedicine. This represents one of the strictest state-level reinstatements of Ryan Haight Act principles. The good news for non-stimulant seekers: this rule specifically targets controlled substances, leaving Strattera and similar medications unaffected.

Georgia prohibits nurse practitioners from prescribing Schedule II medications even under physician supervision, limiting stimulant access through NP-led telehealth platforms. Physicians can still prescribe all ADHD medications via telehealth, and NPs can prescribe non-controlled options like Strattera with their collaborative practice agreements.

Who Can Prescribe ADHD Medications via Telehealth?

Physicians (MD/DO)

Licensed physicians in all 50 states can prescribe both stimulant and non-stimulant ADHD medications via telehealth, provided they:

• Hold an active medical license in your state
• Maintain DEA registration (for controlled substances)
• Follow applicable state telehealth laws
• Conduct evaluations meeting the standard of care

Nurse Practitioners and Physician Assistants

The picture for advanced practice providers varies significantly by state:

Independent Practice States (including New York, Illinois, and New Hampshire): Nurse practitioners can practice independently and prescribe ADHD medications—including both stimulants and non-stimulants—after meeting experience requirements. These states recognize NPs as autonomous practitioners following completion of specified clinical hours.

Collaborative Practice States (including Florida, California, and Pennsylvania): NPs and PAs must maintain agreements with supervising physicians. While they can prescribe non-controlled medications like Strattera relatively freely, stimulant prescribing authority depends on state law and the scope of their collaborative agreement.

Restricted States (including Georgia and Texas): These states significantly limit Schedule II prescribing by NPs and PAs. In Texas, NPs can only prescribe Schedule II stimulants in hospital or hospice settings. In Georgia, NPs cannot prescribe Schedule II controlled substances at all, even with physician oversight. However, both states allow NP/PA prescribing of non-stimulant medications under appropriate supervision.

When choosing a telehealth platform, verify that providers hold proper credentials for your state. Quality services like Klarity Health carefully match patients with appropriately licensed clinicians who can legally prescribe in your location.

What to Expect from a Legitimate Telehealth ADHD Evaluation

The Comprehensive Assessment Process

Reputable telehealth ADHD evaluations are not shortcuts—they follow the same diagnostic rigor as in-person assessments. Expect your initial consultation to include:

Detailed Symptom Review: Your provider will ask about current ADHD symptoms across multiple life domains (work, school, relationships, daily functioning). They’ll use structured questions based on DSM-5 diagnostic criteria, which require evidence of symptoms causing impairment in at least two settings.

Developmental History: ADHD symptoms must have been present before age 12. Your clinician will explore childhood experiences, school performance, and early behavioral patterns. For adults seeking diagnosis, this might involve reviewing old report cards or discussing memories with family members.

Medical and Psychiatric History: Expect questions about previous mental health treatment, current medications, substance use history, and medical conditions. This helps rule out other explanations for attention problems (like thyroid disorders, sleep apnea, or depression) and identifies any contraindications to medication.

Rating Scales and Questionnaires: Many providers use validated assessment tools like the Adult ADHD Self-Report Scale (ASRS) or Conners’ Rating Scales. You might complete these before your appointment.

Collateral Information: Some clinicians request input from family members, partners, or close friends who can provide external perspective on your symptoms and functioning.

Red Flags in Telehealth Prescribing

Be cautious of services that:

• Guarantee medication prescriptions before evaluation
• Complete assessments in under 15 minutes
• Don’t require video consultations (phone-only for initial visits)
• Fail to review your medical history or medication list
• Don’t discuss non-medication treatment options
• Avoid questions about substance use or previous treatment

These practices suggest inadequate clinical oversight. Legitimate telehealth providers prioritize safety and accuracy over convenience.

The ADHD telehealth industry faced significant scrutiny in 2022–2023 when major platforms like Cerebral and Done came under DEA and Department of Justice investigation for allegedly over-prescribing stimulants without proper evaluation. These cases prompted industry-wide tightening of standards. By 2025, reputable platforms have implemented more thorough screening, regular follow-ups, and coordination with other healthcare providers.

Special Considerations for Strattera Prescribing

Medical Screening

Before prescribing Strattera, your provider will screen for contraindications:

Absolute Contraindications:

• Current or recent (within 14 days) use of monoamine oxidase inhibitor (MAOI) antidepressants
• Narrow-angle glaucoma
• Known hypersensitivity to atomoxetine

Relative Contraindications Requiring Careful Evaluation:

• Cardiovascular disease or structural heart abnormalities
• Hypertension (Strattera can increase blood pressure and heart rate)
• Liver disease (rare cases of severe liver injury have been reported)
• History of bipolar disorder (can trigger manic episodes)
• History of suicidal ideation (FDA black box warning about increased suicidal thinking in children and adolescents)

Your telehealth provider will review these factors during your evaluation. If significant concerns exist, they may order additional testing, request records from other providers, or recommend in-person specialty consultation before starting medication.

Monitoring and Follow-Up

Strattera requires ongoing monitoring, which can be effectively managed via telehealth:

Initial Titration Period (Weeks 0–8): Most providers schedule follow-ups every 2–4 weeks as you start medication and adjust dosing. You’ll discuss symptom improvement, side effects, blood pressure changes, and any concerns.

Maintenance Phase: Once stabilized on an effective dose, follow-ups typically occur every 1–3 months. Your provider will assess continued effectiveness, monitor for side effects, and evaluate overall functioning.

Vital Sign Monitoring: You may be asked to monitor blood pressure and heart rate at home, especially during dose adjustments. Many patients use home blood pressure monitors and report findings at appointments.

Prescription Details

As a non-controlled substance, Strattera offers practical advantages:

Supply Duration: Providers can prescribe 90-day supplies (versus 30-day limits for stimulants), reducing the frequency of pharmacy visits and follow-up appointments.

Refills: Multiple refills can be authorized on a single prescription (typically up to 5 refills or 6 months, depending on state law), unlike Schedule II stimulants that require a new prescription each month.

Electronic Prescribing: While e-prescribing is recommended and often required by state law, Strattera doesn’t face the same strict DEA electronic prescribing requirements as controlled substances.

Pharmacy Access: Because it’s not controlled, Strattera faces minimal scrutiny at pharmacies. You won’t encounter the same verification hurdles or supply shortages that sometimes affect stimulant medications.

Prescription Monitoring Programs: What Patients Should Know

Although Strattera isn’t tracked in Prescription Drug Monitoring Programs (PDMPs), understanding these systems helps contextualize the broader ADHD treatment landscape.

State PDMP Requirements

Most states mandate that prescribers check the state PDMP database before prescribing controlled substances:

• Florida: Requires checking before every controlled substance prescription
• California: Mandates checks at least every four months for ongoing controlled substance therapy
• Pennsylvania: Requires PDMP review at first prescription and every 90 days thereafter
• New Hampshire: Mandates checks for each controlled substance prescription

While these requirements don’t apply to Strattera, expect your telehealth provider to review your controlled substance prescription history as part of comprehensive care. This helps identify:

• Potential drug interactions with current medications
• Patterns suggesting substance use concerns
• Whether you’re receiving overlapping prescriptions from multiple providers

This isn’t about distrust—it’s standard clinical practice ensuring your safety. Responsible telehealth providers view PDMP review as a tool for coordinating care, not surveillance.

Patient Eligibility and When Telehealth May Not Be Appropriate

Ideal Candidates for Telehealth ADHD Treatment

You’re likely a good candidate for telehealth-based ADHD treatment if you:

• Have relatively stable mental and physical health
• Can participate effectively in video consultations
• Have reliable internet access and a private space for appointments
• Are willing to provide thorough history and follow treatment recommendations
• Have no concerning patterns of medication misuse
• Can arrange for vital sign monitoring (blood pressure, heart rate) if prescribed medication

Situations Requiring In-Person Evaluation

Telehealth may not be suitable—at least initially—if you have:

Complex Medical Conditions: Uncontrolled cardiovascular disease, severe hypertension, significant liver disease, or other serious medical issues may require in-person specialist evaluation before starting ADHD medication.

Acute Psychiatric Instability: Active suicidal ideation, uncontrolled bipolar disorder, acute psychosis, or recent psychiatric hospitalization typically warrant in-person psychiatric care.

Substance Use Concerns: Active substance use disorder or recent history of stimulant misuse may require in-person addiction medicine evaluation and treatment before ADHD medication consideration.

Diagnostic Complexity: If symptoms overlap significantly with other conditions (autism spectrum disorder, complex trauma, learning disabilities), comprehensive neuropsychological testing may be needed—something typically done in person.

Age Considerations: Most telehealth platforms serve adults (18+) for controlled substance prescribing, though some accept adolescents with parental involvement. Young children (under 12) typically require in-person pediatric ADHD evaluation.

Previous Treatment Complications: If you’ve had severe medication reactions, multiple medication failures, or complex treatment history, a telehealth provider may refer you to in-person specialty care for more intensive evaluation.

A responsible telehealth provider will recognize these situations and either coordinate with your existing care team or refer you to appropriate in-person resources. This isn’t a failure of telehealth—it’s evidence of good clinical judgment.

How Klarity Health Approaches ADHD Treatment

At Klarity Health, we recognize that accessing mental healthcare shouldn’t require navigating an obstacle course of appointments, insurance headaches, and long waitlists. Our approach to ADHD treatment balances convenience with clinical rigor.

Provider Availability and Expertise

We connect patients with licensed medical doctors and nurse practitioners who specialize in adult ADHD and related conditions. Our providers are:

• Licensed in your specific state
• Trained in evidence-based ADHD assessment and treatment
• Experienced in telehealth best practices
• Committed to thorough, individualized evaluations (not cookie-cutter assessments)

Initial consultations typically last 30–60 minutes—time enough for comprehensive evaluation. We don’t rush diagnoses or guarantee prescriptions. Instead, we prioritize accurate assessment and appropriate treatment recommendations.

Transparent Pricing and Insurance Options

Healthcare costs shouldn’t be a mystery. Klarity offers:

Insurance Coverage: We accept many major insurance plans, helping you maximize benefits and minimize out-of-pocket costs. Our team verifies coverage before your appointment so you know what to expect.

Cash-Pay Options: For those without insurance or who prefer not to use it, we offer straightforward cash pricing. No hidden fees or surprise bills—you’ll know the cost upfront.

This dual approach ensures access regardless of insurance status, removing a common barrier to mental healthcare.

Comprehensive Treatment Planning

ADHD treatment isn’t just about medication. Our providers discuss:

• Behavioral strategies and organizational tools
• Lifestyle modifications (sleep hygiene, exercise, nutrition)
• Therapy referrals when appropriate (CBT, coaching, support groups)
• Coordination with other healthcare providers
• Educational resources about ADHD in adults

For patients starting non-stimulant medication like Strattera, we provide realistic expectations about timeline (4–6 weeks to full effect), potential side effects, and what to monitor. We schedule appropriate follow-ups to adjust treatment based on your response.

Medication Management and Monitoring

Our prescribing practices reflect current best standards:

• Comprehensive medical screening before starting medication
• Regular follow-up appointments to assess effectiveness and safety
• Vital sign monitoring protocols
• Clear communication about when to seek additional care
• Coordination with your primary care provider (with your permission)

For Strattera and other non-controlled medications, we can provide longer prescription durations (typically 90 days) with appropriate refills, reducing the burden of monthly pharmacy visits.

Practical Tips for Successful Telehealth ADHD Treatment

Before Your First Appointment

Gather Documentation: Collect any relevant records—previous ADHD evaluations, psychiatric treatment summaries, relevant medical records. Old report cards or school evaluations can be particularly valuable for establishing childhood symptoms.

List Current Medications: Know what you’re taking, including doses, frequencies, and the purpose of each medication. Include over-the-counter supplements.

Prepare Your Environment: Find a private, quiet space with good lighting and reliable internet. Use headphones if privacy is a concern. Make sure your device is charged.

Think Through Your History: Before the appointment, reflect on:

• When you first noticed attention difficulties
• How symptoms affect different areas of your life
• Previous treatments you’ve tried and their outcomes
• Family history of ADHD or related conditions
• Your goals for treatment

Be Honest About Substance Use: Current or past substance use doesn’t automatically disqualify you from treatment, but providers need accurate information to prescribe safely. Honesty protects your health.

During Your Evaluation

Be Thorough and Specific: When describing symptoms, give concrete examples. Instead of ‘I can’t focus,’ try ‘I start reading work emails but find myself browsing news sites without realizing how I got there.’

Acknowledge Uncertainties: If you don’t remember childhood details or aren’t sure about something, say so. Providers understand that memory isn’t perfect, especially over decades.

Ask Questions: If you don’t understand something, ask for clarification. Good providers welcome questions about:

• The diagnostic process
• Treatment options and their pros/cons
• Expected timelines for improvement
• Potential side effects
• Follow-up plans
• Costs and insurance coverage

Discuss Your Preferences: If you have strong feelings about medication versus non-medication approaches, or preferences among medication options, share these. Effective treatment requires buy-in, and your provider should incorporate your values and goals.

After Starting Medication

Track Your Response: Keep notes about:

• Symptom improvements (be specific—what tasks are easier?)
• Side effects (type, severity, timing, duration)
• Sleep quality
• Appetite changes
• Mood and energy levels
• Blood pressure and heart rate (if monitoring at home)

Follow the Treatment Plan: Take Strattera as prescribed—daily, at the same time, with or without food (but consistently). Don’t skip doses or stop abruptly without consulting your provider.

Attend Follow-Ups: These appointments aren’t optional paperwork—they’re crucial for optimizing your treatment. Your provider needs feedback to adjust dosing, address side effects, or consider alternative approaches if needed.

Communicate Promptly About Concerns: Between appointments, contact your provider if you experience:

• Severe or distressing side effects
• Thoughts of self-harm
• Significant mood changes
• Chest pain, severe headaches, or other alarming symptoms
• No improvement after adequate trial period

Coordinate with Other Providers: With your permission, your telehealth psychiatrist should communicate with your primary care physician and any therapists. This collaborative approach produces better outcomes.

Managing Prescriptions and Pharmacy Relationships

Choose One Pharmacy: Using the same pharmacy consistently helps pharmacists track your medications, identify potential interactions, and alert you to issues. It also simplifies the process of refills and transfers.

Understand Electronic Prescribing: Most telehealth prescriptions are sent electronically to your chosen pharmacy. You’ll typically receive a notification when it’s ready for pickup or can be mailed.

Plan Ahead for Refills: Don’t wait until you’re out of medication to request refills. Request them a week early to account for provider response time, pharmacy processing, and potential supply issues.

Know Your Insurance Formulary: Check whether Strattera is covered by your insurance and at what tier (generic atomoxetine is usually cheaper than brand-name Strattera). Your provider or pharmacy can help identify the most cost-effective option.

Use Manufacturer Discount Programs: If insurance doesn’t cover medication or copays are high, check for manufacturer coupons or patient assistance programs. Pharmaceutical companies often offer these for expensive medications.

Common Myths and Misconceptions

‘Online ADHD Prescriptions Are Too Easy to Get’

Reality: Legitimate telehealth ADHD evaluations are comprehensive, following the same diagnostic criteria and safety protocols as in-person care. While convenience is a benefit, responsible platforms don’t sacrifice thoroughness for speed.

The 2023 controversies involving certain telehealth companies led to industry-wide improvements in evaluation rigor and prescribing oversight. Today’s reputable services have strengthened their clinical protocols precisely to ensure appropriate care.

If a service seems ‘too easy’—guaranteeing prescriptions, skipping detailed evaluations, or not checking medical history—that’s a red flag, not the industry standard.

‘Non-Stimulants Don’t Really Work’

Reality: While stimulants often work faster and have higher response rates, non-stimulants like Strattera are genuinely effective for many patients. Research shows atomoxetine produces meaningful improvement in ADHD symptoms for approximately 60–70% of patients.

Non-stimulants particularly shine for people who:

• Experience uncomfortable stimulant side effects (anxiety, insomnia, appetite suppression)
• Have comorbid anxiety disorders (stimulants can worsen anxiety)
• Are concerned about potential for misuse
• Need 24-hour symptom coverage
• Have tic disorders (stimulants can exacerbate tics)

The key is setting realistic expectations: Strattera takes 4–6 weeks to reach full effectiveness, versus stimulants’ same-day action. Different doesn’t mean inferior—it means finding the right match for your specific situation.

‘Telehealth Doctors Can’t Prescribe Controlled ADHD Medications’

Reality: Under current federal rules (extended through December 31, 2025), qualified providers can prescribe controlled substances including stimulants via telehealth, provided they meet state requirements and maintain proper DEA registration.

Thousands of patients successfully receive stimulant ADHD medications through telehealth. The uncertainty involves future regulations—current flexibilities may expire without extension—but as of late 2025, telehealth prescribing of controlled medications remains legal under federal law.

For non-stimulants like Strattera, there was never a prohibition. These medications have always been accessible via telehealth under standard prescribing practices.

‘Pharmacies Won’t Fill Telehealth Prescriptions’

Reality: Most pharmacies routinely fill telehealth prescriptions from licensed practitioners. Electronic prescriptions don’t distinguish between telehealth and in-person visits.

Some pharmacies did increase scrutiny of telehealth stimulant prescriptions in 2023 following media coverage of prescribing concerns, but this primarily affected controlled substances from lesser-known platforms. Using reputable telehealth services and maintaining consistent pharmacy relationships minimizes any potential friction.

For Strattera and other non-controlled medications, pharmacy filling is typically straightforward with no special questions or verification beyond standard practice.

‘Telehealth Treatment Is Less Effective Than In-Person Care’

Reality: Research on telehealth mental healthcare consistently shows comparable outcomes to in-person treatment for appropriately selected patients and conditions. For ADHD in particular, studies demonstrate that:

• Diagnostic accuracy via video is similar to in-person evaluation
• Treatment adherence may actually improve due to reduced barriers (no travel, easier scheduling)
• Patient satisfaction is high
• Clinical outcomes (symptom reduction, functional improvement) are equivalent

The key phrase is ‘appropriately selected patients.’ Telehealth works best for stable patients with straightforward presentations. Complex cases may benefit from in-person specialty evaluation, but for many adults with ADHD, telehealth represents genuinely effective care—not a compromise.

Looking Ahead: The Future of Telehealth ADHD Treatment

Regulatory Evolution

The telehealth landscape continues evolving. As the current DEA extension approaches its December 31, 2025 expiration, several scenarios could unfold:

Fourth Extension: The DEA may issue another temporary extension, maintaining current telehealth prescribing flexibilities into 2026. This appears likely given ongoing regulatory review processes and the OMB’s current evaluation of proposed permanent rules.

Permanent Framework: The DEA has proposed a ‘Special Registration’ system that could create permanent telehealth pathways with specific safeguards. If finalized, this could provide long-term clarity and stability for telehealth prescribing.

Partial Rollback: It’s possible that some flexibility could end while other provisions continue, creating a hybrid model. For instance, ongoing prescriptions might continue via telehealth while new patients require in-person evaluation.

Full Reversion: Theoretically, COVID-era flexibilities could fully expire, reimposing the Ryan Haight Act’s in-person requirement for controlled substances. This seems unlikely given widespread use and documented benefits, but regulatory outcomes aren’t always predictable.

What This Means for You: If you’re starting non-stimulant treatment, regulatory uncertainty shouldn’t affect your access—Strattera and similar medications remain fully available via telehealth regardless of DEA policy changes.

If you’re considering or currently using stimulant medications via telehealth, stay informed through your provider’s communications. Reputable platforms will notify patients well in advance of any required changes and help coordinate continuity of care.

State-Level Trends

States continue refining telehealth regulations, with mixed directions:

Expansion: More states are adopting permanent telehealth parity laws, recognizing video consultations as equivalent to in-person visits for establishing provider-patient relationships and prescribing. New Hampshire’s 2025 reforms exemplify this trend.

Targeted Restrictions: Some states are implementing new safeguards specifically for controlled substance prescribing while maintaining broad telehealth access for other conditions. New York’s 2025 in-person requirement for controlled substances represents this approach.

Scope of Practice Evolution: Ongoing debates about nurse practitioner and physician assistant prescribing authority will continue shaping who can provide telehealth ADHD treatment. Some states are expanding APRN independence while others maintain collaborative requirements.

Technology Integration: States are increasingly requiring PDMP integration, electronic prescribing, and other technological safeguards as conditions of telehealth prescribing, particularly for controlled substances.

Patient Advocacy Matters

Your experience with telehealth shapes these policies. When regulatory agencies request public comment on proposed rules (as the DEA did for its telehealth proposals), patient input carries significant weight.

Organizations advocating for telehealth access and mental health parity welcome patient voices. If telehealth has meaningfully improved your access to ADHD treatment, consider:

• Responding to federal comment periods when announced
• Connecting with mental health advocacy organizations
• Sharing your story with legislators (state and federal)
• Supporting evidence-based policy approaches that balance access and safety

Taking the Next Step

If you’re struggling with ADHD symptoms and traditional in-person care hasn’t worked due to scheduling challenges, long waitlists, or other barriers, telehealth offers a genuine alternative—not a second-best option, but a legitimate pathway to evidence-based treatment.

Non-stimulant medications like Strattera provide effective ADHD management for many people, with the added benefit of being fully accessible through telehealth without the regulatory complications affecting controlled substances. Whether you’re seeking non-stimulants as a first-line treatment or because stimulants haven’t worked well, comprehensive evaluation and treatment are available through virtual care.

What to Do Now

If you’re ready to explore telehealth ADHD treatment:

1. Research reputable platforms that use licensed clinicians, require comprehensive video evaluations, and follow evidence-based diagnostic criteria. Look for services with transparent pricing and clear clinical protocols.

2. Verify state licensure of any provider you’ll see. Confirm they’re licensed in your state and, if prescribing controlled substances, hold proper DEA registration.

3. Check your insurance coverage if planning to use insurance, or review cash-pay pricing if going that route. Many services, including Klarity Health, offer both options with transparent cost information.

4. Gather relevant documentation: previous evaluations, medication lists, medical records that might inform your assessment.

5. Prepare for a thorough evaluation: Set aside adequate time, find a private space, and be ready to discuss your symptoms, history, and treatment goals in detail.

6. Consider your treatment preferences: Think about whether you’re interested in medication (stimulant or non-stimulant), therapy, or both. Effective providers should offer comprehensive approaches tailored to your needs.

If you have questions or concerns: Don’t let uncertainty prevent you from seeking care. Reputable telehealth platforms have patient support teams who can answer questions about the process, costs, what to expect, and whether their services might be right for you.

ADHD doesn’t have to control your life. With appropriate evaluation and treatment—delivered through the convenience of telehealth—you can develop strategies and access medications that make real differences in your daily functioning, relationships, work performance, and overall quality of life.

At Klarity Health, our providers are ready to conduct thorough ADHD evaluations, discuss your full range of treatment options including non-stimulant medications like Strattera, and develop individualized treatment plans that fit your life. With flexible appointment availability, transparent pricing that works with insurance or cash pay, and ongoing support throughout your treatment journey, accessing quality ADHD care has never been more straightforward.

The first step is reaching out. From there, we’ll work together to understand your symptoms, confirm a diagnosis if appropriate, and build a treatment plan designed around your unique needs and goals.

Citations

1. ‘The Drug Enforcement Administration finalized a one-year extension of controlled substance prescribing via telehealth,’ Fierce Healthcare, November 2024. www.fiercehealthcare.com

2. ‘DEA Signals Extension of Telemedicine Flexibilities for Controlled Substance Prescribing for 2026,’ McDermott Will & Emery, December 2025. www.mwe.com

3. ‘Telehealth and In-Person Visits: Tracking Federal and State Updates to Pandemic-Era Telehealth Exceptions,’ Sheppard Mullin Healthcare Law Blog, August 15, 2025. www.sheppardhealthlaw.com

4. ‘Telehealth Compliance Trap: The Hidden Catch-22 Threatening Your Practice,’ RxAgent.co, October 2025. www.rxagent.co

5. ‘Is Strattera a Controlled Substance?,’ Medical News Today, January 14, 2025. www.medicalnewstoday.com

Source:

• https://www.fiercehealthcare.com/regulatory/dea-finalizes-one-year-extension-controlled-substance-prescribing-telehealth-punts-final#:~:text=The%20Drug%20Enforcement%20Administration%20,Federal%20Register%20on%20Friday%20night
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=visit,examination%20through%20December%2031%2C%202025
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=A%20new%20rule%20posted%20on,date%20of%20December%2031%2C%202025
• https://www.fiercehealthcare.com/regulatory/dea-finalizes-one-year-extension-controlled-substance-prescribing-telehealth-punts-final#:~:text=The%20%E2%80%9CThird%20Temporary%20Extension%20of,14
• https://www.medicalnewstoday.com/articles/drugs-is-strattera-a-controlled-substance#:~:text=Strattera%20,such%20as%20mental%20health%20issues
• https://www.sheppardhealthlaw.com/2025/08/articles/telehealth/telehealth-and-in-person-visits-tracking-federal-and-state-updates-to-pandemic-era-telehealth-exceptions/#:~:text=In%20late%202024%2C%20the%20U,prescribing
• https://www.rxagent.co/blog/telehealth-compliance-trap#:~:text=The%20,False%20Hope
• https://www.techtarget.com/virtualhealthcare/news/366616019/Telehealth-prescribing-flexibility-extended-through-2025#:~:text=Image%20filo%2FDigitalVision%20Vectors%20via%20G,The
• https://natlawreview.com/article/telehealth-and-person-visits-tracking-federal-and-state-updates-pandemic-era?amp=#:~:text=Extend%20natlawreview,before%20issuing%20a%20dangerous%20drug
• https://www.rxagent.co/blog/telehealth-compliance-trap#:~:text=,specifically%20for%20chronic%20pain%20treatment